Impulsivity Domains and Subjective Response
Alcohol Use Disorder
About this trial
This is an interventional basic science trial for Alcohol Use Disorder focused on measuring Addiction, Alcohol, Young adult, Impulsivity, Prevention, Subjective response
Eligibility Criteria
Inclusion Criteria: 21-25 years old Report drinking to an estimated BAC > .08% at least once in the past 30 days based on responses on the Timeline Followback (TLFB) Report drinking at least twice weekly in the past 30 days based on responses on the TLFB Fluency in English Exclusion Criteria: Any serious medical problems (e.g., liver disease, cardiac abnormality, pancreatitis, diabetes, neurological problems, and gastrointestinal disorders) Body weight < 110 or > 210 pounds Axis I psychiatric disorders including substance use disorder other than mild or moderate alcohol or mild cannabis use disorder Current alcohol withdrawal or history of medically-assisted detoxification Two positive breath alcohol concentration (BrAC) readings (i.e., > 0.00%) at an in-person screening appointment or experimental session Positive urine screen for illegal drugs other than cannabis Currently seeking or past-12-month history of inpatient or intensive treatment for addictive behaviors Current psychotropic medication use or receipt of a prescription for these medications in the past 30 days Psychosis or other psychiatric disability Pregnancy, nursing or lack of reliable birth control use for women Report smoking > 5 cigarettes per day (to avoid acute nicotine effects or withdrawal during experimental sessions)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Alcohol, Then Placebo, then Free-access session
Placebo, Then Alcohol, then Free-access session
participants will complete two intravenous administration sessions in the lab during which they will receive alcohol then placebo (saline), followed by a third lab session in which they will have free-access to self-administer alcohol (up to 120mg% BrAC) and placebo intravenously for 60 min
participants will complete two intravenous administration sessions in the lab during which they will receive placebo (saline) then alcohol, followed by a third lab session in which they will have free-access to self-administer alcohol (up to 120mg% BrAC) and placebo intravenously for 60 min